High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
Ashraf Badros(University of Maryland, Baltimore), Guido Tricot, Nikhil C. Munshi(Dana-Farber Cancer Institute), Michele Cottler‐Fox(University of Arkansas for Medical Sciences), Raman Desikan(White River Technologies (United States)), Christopher Morris(University of South Florida), Amir A. Toor(Virginia Commonwealth University), Maurizio Zangari(University of Arkansas for Medical Sciences), Sara Romero-Martín(University of Arkansas for Medical Sciences), Steven A. Schichman(Central Arkansas Veterans Healthcare System), Elias Anaissie(Clinical Trial and Consulting), Bart Barlogie(University of Arkansas for Medical Sciences), Jayesh Mehta(Northwestern University), Athanasios Fassas(University of Arkansas for Medical Sciences)
Cited by 188
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k